Changchun, China

Junzhe Wu

This inventor holds 1 USPTO granted patent. Top assignee: Jilin University. Active years: 2025.


% Patents Active = 100.0

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Junzhe Wu in Anti-Colitis Drug Development

Introduction

Junzhe Wu is an accomplished inventor based in Changchun, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of treatments for inflammatory bowel disease. His innovative work has garnered attention for its potential impact on patient care.

Latest Patents

Junzhe Wu holds a patent for the "Use of oleanolic acid-28-O-beta-D-glucopyranoside in preparation of anti-colitis drug." This patent highlights the use of oleanolic acid-28-O-β-D-glucopyranoside, which exhibits significant anti-ulcerative-colitis activity compared to its parent compound, oleanolic acid, and other analogues. The compound demonstrates equivalent efficacy to Mesalazine, a first-line treatment for inflammatory bowel disease, while also minimizing the risk of salicylic acid anaphylaxis associated with Mesalazine treatment. This innovation presents a promising application prospect for patients suffering from colitis.

Career Highlights

Junzhe Wu is affiliated with Jilin University, where he continues to advance his research and development efforts. His work is characterized by a commitment to improving therapeutic options for patients with gastrointestinal disorders. His patent reflects his dedication to addressing unmet medical needs in this area.

Collaborations

Junzhe Wu collaborates with esteemed colleagues, including Haoming Lv and Hongqiang Lin. Their combined expertise contributes to the advancement of research and innovation in the field of pharmaceuticals.

Conclusion

Junzhe Wu's contributions to the development of anti-colitis drugs exemplify the importance of innovation in healthcare. His work not only enhances treatment options but also improves the quality of life for patients with inflammatory bowel disease.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…